[Form 4] Tonix Pharmaceuticals Holding Corp. Insider Trading Activity

Rhea-AI Filing Summary

Tonix Pharmaceuticals insider purchase by Director Carolyn E. Taylor: The reported transaction shows Director Carolyn E. Taylor acquired 418 shares of Tonix Pharmaceuticals Holding Corp. common stock at a weighted-average purchase price of $36.03 per share, with individual purchase prices ranging from $35.98 to $36.05. The transaction is reported as a direct purchase under Rule 16 reporting. The filing was submitted by an attorney-in-fact on behalf of the reporting person. No derivative transactions, dispositions, or additional holdings beyond the 418 shares are disclosed in this Form 4.

Positive

• Insider purchase disclosed, indicating transparency in compliance with Section 16 reporting requirements
• Clear pricing detail provided: weighted-average price $36.03 and actual prices ranged from $35.98 to $36.05

Negative

• None.

Insights

Securities Analyst

TL;DR Director acquired a small number of shares at market prices; immaterial to company capitalization but relevant for insider activity tracking.

This Form 4 reports a straight purchase of 418 shares by a company director at an average price of $36.03 per share, with execution prices between $35.98 and $36.05. The disclosure is limited to a single non-derivative acquisition and identifies direct beneficial ownership. From a market-impact perspective, the transaction size appears small relative to typical public-company float and does not indicate any change in control or significant capital transfer. The filing fulfills Section 16 reporting requirements and provides transparency on insider behavior without revealing a trading plan or material strategic information.

Corporate Governance Expert

TL;DR Routine insider purchase disclosure by a director; complies with reporting rules and adds transparency to insider holdings.

The report documents a non-derivative purchase by a director, filed individually and signed by an attorney-in-fact. The acquisition of 418 shares at an average of $36.03 is a straightforward transaction and is clearly described, including the range of actual prices paid. There are no accompanying derivative grants, disposals, or indications of a Rule 10b5-1 plan in the text provided. For governance monitoring, this is a standard disclosure that updates the director's stake without indicating governance changes or related-party transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Carolyn E.

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

26 MAIN STREET, SUITE 101

(Street)

CHATHAM NJ 07928

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001	08/21/2025		P		418	A	$36.03(1)	418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average purchase price. Actual purchase prices ranged from $35.98 to $36.05.

	/s/ Jessica Morris as attorney-in-fact	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Tonix (TNXP) director Carolyn E. Taylor report?

The director reported a direct purchase of 418 shares of Tonix common stock.

At what price were the TNXP shares purchased by the reporting director?

The weighted-average purchase price was $36.03 per share; individual prices ranged from $35.98 to $36.05.

Does the Form 4 report any derivative transactions or sales by the director?

No. The Form 4 only reports a non-derivative acquisition of common stock and no derivatives or dispositions are listed.

Was the Form 4 filed jointly or by one reporting person for TNXP?

The form indicates it was filed by one reporting person (individual filing).

Who signed the Form 4 for the reporting person?

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.